The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
HER2-Targeted Therapy Reduces Incidence and Progression of Midlife Mammary Tumors in Female Murine Mammary Tumor Virus huHER2-Transgenic Mice
Open accessAbstract
PURPOSE: This study examined the effectiveness of early and prolonged mu4D5 (the murine form of trastuzumab/Herceptin) treatment in transgenic mice that overexpress human HER2 (huHER2), under the murine mammary tumor virus promoter, as a model of huHER2-overexpressing breast cancer. EXPERIMENTAL DESIGN: Mice were randomly assigned to one of three treatment groups and received i.p. injections from 17 weeks of age until either 52 weeks of age or morbidity. Fourteen mice received 100 mg/kg mu4D5, 14 mice received 100 mg/kg antiherpes simplex virus glycoprotein D control antibody, and 11 mice received a diluent control. RESULTS: High levels of huHER2 expression were detectable in mammary glands of young virgin founder mice. Mammary adenocarcinomas were frequently found in female founders and progeny at an average age of 28 weeks, with some progressing to metastatic disease. The incidence of mammary tumors was significantly reduced, and tumor growth inhibition was observed in mice receiving mu4D5 compared with control mice. In addition, Harderian gland neoplasms, highly associated with overexpression of huHER2 in this transgenic line, were entirely absent in the mu4D5 treatment group, indicating down-regulation of huHER2 in vivo activity. CONCLUSIONS: Early intervention with mu4D5 was of benefit in our transgenic mice at high risk for developing huHER2-overexpressing breast cancer. This study suggests a potential benefit of early treatment with Herceptin in HER2-positive primary breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Overexpression of wild-type Neu or HER2 under a mammary-specific promoter leads to metastatic mammary tumors in transgenic mice.
“Consistent with its oncogenic activity, overexpression of wild-type Neu or HER2 under the control of a mammary-specific promoter leads to metastatic mammary tumors in transgenic mice (Andrechek et al., 2000; Finkle et al., 2004).”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Finkle et al., 2004
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W. J., Jones, L. A., Holt, J. A., Wong, S., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J. A., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,817
Cox, D. R., & Oakes, D. (2018) · Chapman & Hall/CRC eBooks · doi:10.1201/9781315137438 · Cited by 6,269
Manipulating the mouse embryo: A laboratory manual
Hogan, B. L. M., Costantini, F. D., & Lacy, E. (1986) · Cited by 4,460
The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice
Adams, J. M., Harris, A. W., Pinkert, C. A., Corcoran, L. M., Alexander, W. S., Cory, S., Palmiter, R. D., & Brinster, R. L. (1985) · Nature · doi:10.1038/318533a0 · Cited by 1,779
Hanahan, D. (1985) · Nature · doi:10.1038/315115a0 · Cited by 1,281
Muller, W., Sinn, E., Pattengale, P., Wallace, R., & Leder, P. (1988) · Cell · doi:10.1016/0092-8674(88)90184-5 · Cited by 1,246
Guy, C. T., Webster, M. A., Schaller, M. D., Parsons, T. J., Cardiff, R. D., & Muller, W. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.22.10578 · Cited by 1,193
ErbB2 is essential in the prevention of dilated cardiomyopathy
Crone, S. A., Zhao, Y., Fan, L., Gu, Y., Minamisawa, S., Liu, Y., Peterson, K. L., Chen, J., Kahn, R., Condorelli, G., et al. (2002) · Nature Medicine · doi:10.1038/nm0502-459 · Cited by 902
Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes
Stewart, T. A., Pattengale, P. K., & Leder, P. (1984) · Cell · doi:10.1016/0092-8674(84)90257-5 · Cited by 892
Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
Sliwkowski, M. X., Ja, L., Gd, L., Te, H., FENDLY, B. M., & Fox, J. A. (1999) · PubMed · Cited by 653
FVB/N: an inbred mouse strain preferable for transgenic analyses.
Taketo, M. M., Schroeder, A. C., Mobraaten, L. E., Gunning, K. B., Hanten, G. R., Fox, R. R., Roderick, T. H., Stewart, C. L., Lilly, F., & Hansen, C. T. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.6.2065 · Cited by 598
High-resolution mapping of mammalian genes by in situ hybridization to free chromatin.
Heng, H. H., Squire, J. A., & Tsui, L.-C. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.20.9509 · Cited by 520
Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies
Phillips, G. D. L., Figari, I. S., FENDLY, B. M., Wong, W. L., Carter, P. M., Gorman, C., & Shepard, H. M. (1993) · Cancer Immunology Immunotherapy · doi:10.1007/bf01518520 · Cited by 500
Self-citationTransgenic mice harboring SV40 t-antigen genes develop characteristic brain tumors
Brinster, R. L., Chen, H. Y., Messing, A., Dyke, T. V., Levine, A. J., & Palmiter, R. D. (1984) · Cell · doi:10.1016/0092-8674(84)90367-2 · Cited by 479
A point mutation in the neu oncogene mimics ligand induction of receptor aggregation
Weiner, D. B., Liu, J., Cohen, J. A., Williams, W. V., & Greene, M. I. (1989) · Nature · doi:10.1038/339230a0 · Cited by 424
Modes of DAPI banding and simultaneous in situ hybridization
Heng, H. H., & Tsui, L. (1993) · Chromosoma · doi:10.1007/bf00661275 · Cited by 397
Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene
Bouchard, L., Lamarre, L., Tremblay, P. J., & Jolicoeur, P. (1989) · Cell · doi:10.1016/0092-8674(89)90331-0 · Cited by 393
Oncogenic activation of the neu‐encoded receptor protein by point mutation and deletion.
Bargmann, C. I., & Weinberg, R. A. (1988) · The EMBO Journal · doi:10.1002/j.1460-2075.1988.tb03044.x · Cited by 317
Novel Activating Mutations in the neu Proto-oncogene Involved in Induction of Mammary Tumors
Siegel, P. M., Dankort, D. L., Hardy, W. R., & Muller, W. J. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.11.7068-7077.1994 · Cited by 213
International Classification of Rodent Tumors. The Mouse
(2001) · Springer eBooks · doi:10.1007/978-3-662-07973-7 · Cited by 197
Sarup, J. C., Johnson, R. M., King, K. L., FENDLY, B. M., Lipari, M. T., Napier, M. A., Ullrich, A., & Shepard, H. M. (1991) · PubMed · Cited by 164
Gerlai, R. T., Pisacane, P. I., & Erickson, S. L. (2000) · Behavioural Brain Research · doi:10.1016/s0166-4328(99)00175-8 · Cited by 144
Self-citationPinkas‐Kramarski, R., Alroy, I., & Yarden, Y. (1997) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/a:1026343528967 · Cited by 114
Translational Control by an Upstream Open Reading Frame in the HER-2/neu Transcript
Child, S. J., Miller, M. K., & Geballe, A. P. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.34.24335 · Cited by 105
Suda, Y., Aizawa, S., Furuta, Y., Yagi, T., Ikawa, Y., Saitoh, K., Yamada, Y., Toyoshima, K., & Yamamoto, T. S. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb08094.x · Cited by 89
ELISA for quantitation of the extracellular domain of p185HER2 in biological fluids
Sias, P. E., Kotts, C. E., Vetterlein, D., Shepard, M., & Wong, W. L. (1990) · Journal of Immunological Methods · doi:10.1016/0022-1759(90)90400-p · Cited by 34
Self-citationBrodie, S. G., Xu, X., Li, C., Kuo, A., Leder, P., & Deng, C. (2001) · Oncogene · doi:10.1038/sj.onc.1204222 · Cited by 27
Chan, R., Muller, W. J., & Siegel, P. M. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb08722.x · Cited by 27
Rao, G. N., Ney, E., & Herbert, R. A. (1997) · Breast Cancer Research and Treatment · doi:10.1023/a:1005822318256 · Cited by 24
Oncogenic activation of Neu/ErbB-2 in a transgenic mouse model for breast cancer.
Wj, M., Ho, J., & Pm, S. (1998) · PubMed · Cited by 23
Role of Herceptin® in Primary Breast Cancer: Views from North America and Europe
Leyland-Jones, B. R., & Smith, I. E. (2001) · Oncology · doi:10.1159/000055406 · Cited by 22
Krinke, G. J., Fix, A. S., Jacobs, M. R., Render, J. A., & Weisse, I. (2001) · Springer eBooks · doi:10.1007/978-3-662-07973-7_10 · Cited by 8
Flagged first, then by citations
Cited by
Sorted by citations
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate
Phillips, G. D. L., Li, G., Dugger, D. L., Crocker, L., Parsons, K. L., Mai, E., Blättler, W. A., Lambert, J. M., Chari, R. V. J., Lutz, R. J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1776 · Cited by 1,708
Self-citationMoasser, M. M. (2007) · Oncogene · doi:10.1038/sj.onc.1210477 · Cited by 1,291
ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
Arteaga, C. L., & Engelman, J. A. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.025 · Cited by 1,048
Junttila, T. T., Li, G., Parsons, K. L., Phillips, G. D. L., & Sliwkowski, M. X. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1090-x · Cited by 544
SLC1A5 Mediates Glutamine Transport Required for Lung Cancer Cell Growth and Survival
Hassanein, M., Hoeksema, M. D., Shiota, M., Qian, J., Harris, B. K., Chen, H., Clark, J. E., Alborn, W. E., Eisenberg, R., & Massion, P. P. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2334 · Cited by 355
Müller, P., Kreuzaler, M., Khan, T. A., Thommen, D. S., Martin, K., Glatz, K., Savic, S., Harbeck, N., Nitz, U. A., Gluz, O., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac4925 · Cited by 354
She, Q., Chandarlapaty, S., Ye, Q., Lobo, J. M., Haskell, K., Leander, K. R., Defeo-Jones, D., Huber, H. E., & Rosen, N. X. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003065 · Cited by 313
RetractedInsights from transgenic mouse models of ERBB2-induced breast cancer
Ursini‐Siegel, J., Schade, B., Cardiff, R. D., & Muller, W. J. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2127 · Cited by 272
Imaging Tumors with an Albumin-Binding Fab, a Novel Tumor-Targeting Agent
Dennis, M. S., Jin, H., Dugger, D. L., Yang, R., McFarland, L. M., Ogasawara, A. K., Williams, S. P., Cole, M. J., Ross, S., & SCHWALL, R. H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2531 · Cited by 254
Self-citationHanker, A. B., Pfefferle, A. D., Balko, J. M., Kuba, M. G., Young, C. D., Sánchez, V., Sutton, C. R., Cheng, H., Perou, C. M., Zhao, J. J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303204110 · Cited by 203
Neuropilin‐1 expression in cancer and development
Jubb, A. M., Strickland, L. A., Liu, S. D., Mak, J., Schmidt, M., & Koeppen, H. (2011) · The Journal of Pathology · doi:10.1002/path.2989 · Cited by 188
Self-citationCD3 bispecific antibody–induced cytokine release is dispensable for cytotoxic T cell activity
Li, J., Piskol, R., Ybarra, R., Chen, Y.-J. J., Li, J., Slaga, D., Hristopoulos, M. L., Clark, R., Modrusan, Z. D., Tótpál, K., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aax8861 · Cited by 184
Molecular predictors of response to trastuzumab and lapatinib in breast cancer
Esteva, F. J., Yu, D., Hung, M., & Hortobágyi, G. N. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.216 · Cited by 170
Antitumor Efficacy of a Bispecific Antibody That Targets HER2 and Activates T Cells
Junttila, T. T., Li, J., Johnston, J., Hristopoulos, M. L., Clark, R. A., Ellerman, D. A., Wang, B.-E., Li, Y., Mathieu, M. A., Li, G., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3622-t · Cited by 159
Korangath, P. C., Barnett, J. D., Sharma, A., Henderson, E. T., Stewart, J., Yu, S.-H., Kandala, S. K., Yang, C.-T., Caserto, J. S., Hedayati, M. A., et al. (2020) · Science Advances · doi:10.1126/sciadv.aay1601 · Cited by 157
Reyzer, M. L., Caldwell, R. L., Dugger, T. C., Forbes, J. T., Ritter, C. A., Guix, M., Arteaga, C. L., & Caprioli, R. M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2231 · Cited by 154
Scaltriti, M., Chandarlapaty, S., Prudkin, L., Aura, C., Jimenez, J., Angelini, P. D., Sánchez, G., Guzman, M., Parra, J. L., Ellis, C., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3407 · Cited by 151
Gross, G., & Eshhar, Z. (2016) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124844 · Cited by 149
Miller, T. W., Forbes, J. T., Shah, C., Wyatt, S. K., Manning, H. C., Olivares, M. G., Sanchez, V. M., Dugger, T. C., Granja, N. D. M., Narasanna, A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1665 · Cited by 130
HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation
Vaught, D. B., Stanford, J. C., Young, C., Hicks, D. J., Wheeler, F., Rinehart, C., Sánchez, V., Koland, J., Muller, W. J., Arteaga, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3594 · Cited by 129
Tumor Elastography and Its Association with Collagen and the Tumor Microenvironment
Riegler, J., Labyed, Y., Rosenzweig, S. J., Javinal, V., Castiglioni, A., Dominguez, C. X., Long, J. E., Li, Q., Sandoval, W. N., Junttila, M. R., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3262 · Cited by 129
Virus-like particle display of HER2 induces potent anti-cancer responses
Palladini, A., Thrane, S., Janitzek, C. M., Pihl, J., Clemmensen, S. B., de Jongh, W. A., Clausen, T. M., Nicoletti, G., Landuzzi, L., Penichet, M. L., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1408749 · Cited by 124
Chandarlapaty, S., Scaltriti, M., Angelini, P. D., Ye, Q., Guzmán, M., Hudis, C. A., Norton, L., Solit, D. B., Arribas, J., Baselga, J. M., et al. (2009) · Oncogene · doi:10.1038/onc.2009.337 · Cited by 125
Target arm affinities determine preclinical efficacy and safety of anti-HER2/CD3 bispecific antibody
Staflin, K., de Zafra, C. L. Z., Schutt, L., Clark, V., Zhong, F., Hristopoulos, M. L., Clark, R., Li, J., Mathieu, M. A., Chen, X., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.133757 · Cited by 107
Pastuskovas, C. V., Mundo, E. E., Williams, S. P., Nayak, T. K., Ho, J., Ulufatu, S., Clark, S., Ross, S., Cheng, E., Parsons-Reponte, K., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0742-t · Cited by 103
Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2 -Amplified Breast Cancers
Joly, M. M., Hicks, D. J., Jones, B. A., Sanchez, V. M., Estrada, M. V., Young, C. D., Williams, M. M., Rexer, B. N., Sarbassov, D. D., Muller, W. J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3393 · Cited by 85
Shah, C., Miller, T. W., Wyatt, S. K., McKinley, E. T., Olivares, M. G., Sanchez, V. M., Nolting, D. D., Buck, J. R., Zhao, P., Ansari, M. S., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2635 · Cited by 83
Activated d16HER2 Homodimers and SRC Kinase Mediate Optimal Efficacy for Trastuzumab
Castagnoli, L., Iezzi, M., Ghedini, G. C., Ciravolo, V., Marzano, G., Lamolinara, A., Zappasodi, R., Gasparini, P., Campiglio, M., Amici, A. R. D., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0983 · Cited by 83
The promise of genetically engineered mice for cancer prevention studies
Green, J. E., & Hudson, T. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1565 · Cited by 82
Turpin, J., Ling, C., Crosby, E. J., Hartman, Z. C., Simond, A. M., Chodosh, L. A., Rennhack, J. P., Andrechek, E. R., Ozcelik, J., Hallett, M. T., et al. (2016) · Oncogene · doi:10.1038/onc.2016.129 · Cited by 79
The Human Splice Variant Δ16HER2 Induces Rapid Tumor Onset in a Reporter Transgenic Mouse
Marchini, C., Gabrielli, F., Iezzi, M., Zenobi, S., Montani, M., Pietrella, L., Kalogris, C., Rossini, A., Ciravolo, V., Castagnoli, L., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018727 · Cited by 75
Venturutti, L., Romero, L., Urtreger, A., Chervo, M., Russo, R., Mercogliano, M., Inurrigarro, G., Pereyra, M., Proietti, C., Izzo, F., et al. (2016) · Oncogene · doi:10.1038/onc.2015.281 · Cited by 65
Phillips, G. D. L., Nishimura, M. C., Lacap, J. A., Kharbanda, S., Mai, E., Tien, J., Malesky, K., Williams, S. P., Mařı́k, J., & PHILLIPS, H. S. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4279-4 · Cited by 66
Self-citationErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapy
Elizalde, P. V., Russo, R. I. C., Chervo, M. F., & Schillaci, R. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0360 · Cited by 68
Quaglino, E., Mastini, C., Amici, A. R. D., Marchini, C., Iezzi, M., Lanzardo, S., Giovanni, C. D., Montani, M., Lollini, P., Masucci, G. V., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2548 · Cited by 61
Garrett, J. T., Rawale, S. V., Allen, S. D., Phillips, G. S., Forni, G., Morris, J. C., & Kaumaya, P. T. P. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.11.7120 · Cited by 58
Zhang, Y. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107677 · Cited by 56
ST3GAL1 and βII-spectrin pathways control CAR T cell migration to target tumors
Hong, Y., Walling, B. L., Kim, H.-R., Serratelli, W. S., Lozada, J. R., Sailer, C. J., Amitrano, A. M., Lim, K., Mongre, R. K., Kim, K., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01498-x · Cited by 50
Quaglino, E., Mastini, C., Forni, G., & Cavallo, F. (2008) · Current Protocols in Immunology · doi:10.1002/0471142735.im2009s82 · Cited by 51
Levin, A. G., Waks, T., & Eshhar, Z. (2014) · Molecular Therapy · doi:10.1038/mt.2014.28 · Cited by 49
Vollmar, B. S., Wei, B. Q., Ohri, R. V., Zhou, J., He, J., Yu, S., Leipold, D. D., Cosino, E., Yee, S. F., Fourie-O’Donohue, A., et al. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00365 · Cited by 46
Castagnoli, L., Ghedini, G. C., Koschorke, A., Triulzi, T., Dugo, M., Gasparini, P., Casalini, P., Palladini, A., Iezzi, M., Lamolinara, A., et al. (2016) · Oncogene · doi:10.1038/onc.2016.338 · Cited by 45
Preclinical models and technologies to advance nanovaccine development
Peres, C., Matos, A. I., Moura, L. I. F., Acúrcio, R. C., Carreira, B., Pozzi, S., Vaskovich‐Koubi, D., Kleiner, R., Satchi‐Fainaro, R., & Florindo, H. F. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.03.001 · Cited by 45
Eshhar, Z. (2014) · Human Gene Therapy · doi:10.1089/hum.2014.2532 · Cited by 43
Li, J., Ybarra, R., Mak, J., Hérault, A., de Almeida, P. E., Arrazate, A., Ziai, J. M., Tótpál, K., Junttila, M. R., Walsh, K. B., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1139 · Cited by 45
Gedik, M. E., Saatci, Ö., Oberholtzer, N. P., Üner, M., Akbulut, Ö., Çetįn, M., Aras, M., İbiş, K., Çalışkan, B., Banoğlu, E., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-2812 · Cited by 40
Korangath, P. C., Lu, J., Yang, C.-T., Healy, S., Guo, X., Ke, S., Grüttner, C., Hu, C., Gabrielson, K., Foote, J. B., et al. (2024) · ACS Nano · doi:10.1021/acsnano.3c12064 · Cited by 40
Wang, S., Astsaturov, I. A., Bingham, C. A., McCarthy, K., von Mehren, M., Xu, W., Alpaugh, R. K., Tang, Y., Littlefield, B. A., Hawkins, L. D., et al. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1090-7 · Cited by 38
Ali, A. I., Wang, M., von Scheidt, B., Domínguez, P. M., Harrison, A. J., Tantalo, D. G. M., Kang, J., Oliver, A. J., Chan, J. D., Du, X., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1141 · Cited by 38
Modeling therapy resistance in genetically engineered mouse cancer models
Rottenberg, S., & Jonkers, J. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2007.11.002 · Cited by 38
KRAS Mouse Models: Modeling Cancer Harboring KRAS Mutations
O’Hagan, R. C., & Heyer, J. (2011) · Genes & Cancer · doi:10.1177/1947601911408080 · Cited by 38
Payload-Binding Fab Fragments Increase the Therapeutic Index of MMAE Antibody–Drug Conjugates
Bordeau, B. M., Nguyen, T. D., Polli, J. R., Chen, P., & Balthasar, J. P. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0440 · Cited by 37
Oncogenic and tumor-suppressive mouse models for breast cancer engaging HER2/neu
Fry, E. A., Taneja, P., & Inoue, K. (2016) · International Journal of Cancer · doi:10.1002/ijc.30399 · Cited by 37
Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2
Giovanni, C. D., Nicoletti, G., Quaglino, E., Landuzzi, L., Palladini, A., Ianzano, M. L., Dall’Ora, M., Grosso, V., Ranieri, D., Laranga, R., et al. (2014) · Breast Cancer Research · doi:10.1186/bcr3602 · Cited by 36
Reddy, S., Shaller, C. C., Doss, M., Shchaveleva, I., Marks, J. D., Yu, J. Q., & Robinson, M. K. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1654 · Cited by 35
The d16HER2 Splice Variant: A Friend or Foe of HER2-Positive Cancers?
Castagnoli, L., Ladomery, M., Tagliabue, E., & Pupa, S. M. (2019) · Cancers · doi:10.3390/cancers11070902 · Cited by 35
Truncated HER2: implications for HER2-targeted therapeutics
Zagożdżon, R., Gallagher, W. M., & Crown, J. P. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.06.003 · Cited by 35
Genetically modified laboratory mice with sebaceous glands abnormalities
Ehrmann, C., & Schneider, M. R. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2312-0 · Cited by 33
Vaccines based on abnormal self-antigens as tumor-associated antigens: Immune regulation
Farkas, A. M., & Finn, O. J. (2010) · Seminars in Immunology · doi:10.1016/j.smim.2010.03.003 · Cited by 31
Clinical applications of mouse models for breast cancer engaging HER2/neu
Fry, E. A., Taneja, P., & Inoue, K. (2016) · Integrative Cancer Science and Therapeutics · doi:10.15761/icst.1000210 · Cited by 27
Liu, B. Y., Soloviev, I., Chang, P., Lee, J., Huang, X.-D., Zhong, C., Ferrara, N., Polakis, P. G., & Sakanaka, C. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008611 · Cited by 28
Chimeric DNA Vaccines: An Effective Way to Overcome Immune Tolerance
Riccardo, F., Bolli, E., Macagno, M., Arigoni, M., Cavallo, F., & Quaglino, E. (2014) · Current topics in microbiology and immunology · doi:10.1007/82_2014_426 · Cited by 28
Chimeric DNA Vaccines against ErbB2+ Carcinomas: From Mice to Humans
Quaglino, E., Riccardo, F., Macagno, M., Bandini, S., Cojoca, R., Ercole, E., Amici, A. R. D., & Cavallo, F. (2011) · Cancers · doi:10.3390/cancers3033225 · Cited by 27
Nagai, Y., Tsuchiya, H., Runkle, E. A., Young, P. D., Ji, M. Q., Norton, L., Drebin, J. A., Zhang, H., & Greene, M. I. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.08.044 · Cited by 25
Palladini, A., Nicoletti, G., Lamolinara, A., Dall’Ora, M., Balboni, T., Ianzano, M. L., Laranga, R., Landuzzi, L., Giusti, V., Ceccarelli, C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17088 · Cited by 25
HER2: defining a Neu target in non-small-cell lung cancer
Ekman, S. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz043 · Cited by 24
Ladjemi, M. Z., Chardès, T., Corgnac, S., Garambois, V., Morisseau, S., Robert, B., Mollévi, C., Aït-Arsa, I., Jacot, W., Pouget, J., et al. (2011) · Breast Cancer Research · doi:10.1186/bcr2826 · Cited by 24
PTPN13 induces cell junction stabilization and inhibits mammary tumor invasiveness
Hamyeh, M., Bernex, F., Larive, R. M., Naldi, A., Urbach, S., Simony-Lafontaine, J., Puech, C., Bakhache, W., Solassol, J., Coopman, P. J. P., et al. (2019) · Theranostics · doi:10.7150/thno.38537 · Cited by 23
Bryson, P. D., Han, X., Truong, N., & Wang, P. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.09.017 · Cited by 23
Gao, Y., & Bergman, I. (2023) · Journal of Virology · doi:10.1128/jvi.00372-23 · Cited by 21
Embryonic Lethality in Homozygous Human Her-2 Transgenic Mice Due to Disruption of the Pds5b Gene
Yong, C. S. M., Sharkey, J., Duscio, B., Venville, B., Wei, W., Jones, R. F., Slaney, C. Y., Arnau, G. M., Papenfuss, A. T., Schröder, J., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0136817 · Cited by 21
Giusti, V., Ruzzi, F., Landuzzi, L., Ianzano, M. L., Laranga, R., Nironi, E., Scalambra, L., Nicoletti, G., Giovanni, C. D., Olivero, M., et al. (2021) · Oncogenesis · doi:10.1038/s41389-021-00360-9 · Cited by 20
Xenogene vaccination in the therapy of cancer
Cavallo, F., Aurisicchio, L., Mancini, R., & Ciliberto, G. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.927433 · Cited by 19
Gao, Y., Whitaker-Dowling, P. A., Griffin, J. A., & Bergman, I. (2012) · Cancer Gene Therapy · doi:10.1038/cgt.2011.90 · Cited by 18
Park, S., Nedrow, J. R., Josefsson, A., & Sgouros, G. (2017) · Oncotarget · doi:10.18632/oncotarget.19174 · Cited by 16
Kondo, M., Cai, Z., Chan, C., Brown, M. K., & Reilly, R. M. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c01071 · Cited by 16
Anti-LYPD1/CD3 T-Cell-Dependent Bispecific Antibody for the Treatment of Ovarian Cancer
Lo, A. A., Johnston, J., Li, J., Mandikian, D., Hristopoulos, M. L., Clark, R., Nickles, D., Liang, W., Hötzel, K., Dunlap, D. Y., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0490 · Cited by 15
Self-citationGinzel, J. D., Acharya, C. R., Lubkov, V., Mori, H., Boone, P. G., Rochelle, L. K., Roberts, W. L., Everitt, J. I., Hartman, Z. C., Crosby, E. J., et al. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0215 · Cited by 16
Taha, Z., Crupi, M. J. F., Alluqmani, N., Fareez, F., Ng, K., Sobh, J., Lee, E., Chen, A., Thomson, M., Spinelli, M. M., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1181014 · Cited by 14
PD-1Hi CAR-T cells provide superior protection against solid tumors
Sailer, C. J., Hong, Y., Dahal, A., Ryan, A. T., Mir, S., Gerber, S. A., Reagan, P. M., & Kim, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1187850 · Cited by 15
Kasuya (2009) · International Journal of Molecular Medicine · doi:10.3892/ijmm_00000332 · Cited by 14
Preclinical vaccines against mammary carcinoma
Lollini, P., Cavallo, F., Giovanni, C. D., & Nanni, P. (2013) · Expert Review of Vaccines · doi:10.1586/14760584.2013.845530 · Cited by 14
HER2 splice variants and their relevance in breast cancer
Sasso, M., Bianchi, F., Ciravolo, V., Tagliabue, E., & Campiglio, M. (2011) · Journal of Nucleic Acids Investigation · doi:10.4081/jnai.2011.2454 · Cited by 14
Levin, A. G., Kronik, N., Shiloach, T., Waks, T., Eshhar, Z., & Vainstein, V. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02516-9 · Cited by 12
Rodrigues, L. M., Stubbs, M., Robinson, S. P., Newell, B., Mansi, J., & Griffiths, J. R. (2004) · Magnetic Resonance Materials in Physics Biology and Medicine · doi:10.1007/s10334-004-0070-8 · Cited by 12
In vivo modeling of the EGFR family in breast cancer progression and therapeutic approaches
Simond, A. M., & Muller, W. J. (2020) · Advances in cancer research · doi:10.1016/bs.acr.2020.04.004 · Cited by 12
Zigler, M., Shir, A., Joubran, S., Sagalov, A., Klein, S., Edinger, N., Lau, J., Yu, S., Mizraji, G., Levin, A. G., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0203 · Cited by 11
Tanaka, T., Suzuki, H., Ohishi, T., Kaneko, M. K., & Kato, Y. (2023) · Cancer Science · doi:10.1111/cas.16008 · Cited by 9
Preclinical HER-2 Vaccines: From Rodent to Human HER-2
Lollini, P., Giovanni, C. D., & Nanni, P. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00151 · Cited by 7
HER2/neu as a Signaling and Therapeutic Marker in Uterine Serous Carcinoma
Ettorre, V. M., Palmieri, L., Clemente, V., & Santin, A. D. (2025) · Cells · doi:10.3390/cells14161282 · Cited by 6
Auni, N. M. A. N. A., Redzwan, N. M., Yahya, M. M., & Wong, K. K. (2025) · International Reviews of Immunology · doi:10.1080/08830185.2025.2545364 · Cited by 6
Report on the use of non‐clinical studies in the regulatory evaluation of oncology drugs
Hayakawa, Y., Kawada, M., Nishikawa, H., Ochiya, T., Saya, H., Seimiya, H., Yao, R., Hayashi, M., Kai, C., Matsuda, A., et al. (2016) · Cancer Science · doi:10.1111/cas.12857 · Cited by 6
HER2-Driven Carcinogenesis: New Mouse Models for Novel Immunotherapies
Marchini, C., Pietrella, L., Kalogris, C., Garulli, C., Gabrielli, F., Quaglino, E., Iezzi, M., Serenella, M., Tagliabue, E., & Amici, A. R. D. (2013) · InTech eBooks · doi:10.5772/53880 · Cited by 6
HER-2/neu Cancer Vaccines: Present Status and Future Prospects
Kaumaya, P. T. P. (2006) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-005-9000-5 · Cited by 6
Dual kinase inhibitor for EGFR mutants and ErbB2 limit breast cancer
Goel, P. N., Zhang, H., Murali, R., Zheng, C., Ji, M. Q., Patterson, A., Grover, P., & Greene, M. I. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.02.019 · Cited by 5
Vasiljević, S., Beale, E. V., Bonomelli, C., Easthope, I. S.-Y., Pritchard, L. K., Seabright, G. E., Caputo, A. T., Scanlan, C. N., Dalziel, M., & Crispin, M. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.08.014 · Cited by 4
5.8S rRNA forms and ribosome heterogeneity in breast cancer
Venturi, G., Zacchini, F., Ruzzi, F., Corradini, A. G., Serra, M., Penzo, M., Treré, D., Lollini, P., & Montanaro, L. (2025) · Biochimie · doi:10.1016/j.biochi.2025.05.010 · Cited by 3
Kennedy, B. B., Raza, M., Mirza, S., Rajan, A. R., Oruji, F., Storck, M. D., Lele, S. M., Reznicek, T. E., Li, L., Rowley, M. J., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217959 · Cited by 3
Models for Evaluation of Targeted Therapies of Invasive and Metastatic Disease
Eccles, S. A. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-968-0_19 · Cited by 2
Promoting Gene Therapy: Expression Systems for Iransgenes and Post-transcriptional Gene Silencing
Unwalla, H. J., & Rossi, J. J. (2006) · Biotechnology and Genetic Engineering Reviews · doi:10.1080/02648725.2006.10648079 · Cited by 2
Metadata
- Authors
- Finkle, D., Quan, Z. R., Asghari, V., Kloss, J., Ghaboosi, N., Mai, E., Wong, W. L., Hollingshead, P., Schwall, R., Koeppen, H., & Erickson, S.
- Affiliations
- 1Physiology, Departments of
- 2Assay and Automation Technology,
- Molecular Oncology (United States) (US)
- Genentech (US)
- Venue
- Clinical Cancer Research
- Published
- 2004-04-01
- Volume
- 10
- Issue
- 7
- Pages
- 2499-2511
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2166433072
- Cited by
- 125
- References
- 33
- Citations by year
- 2025: 5 · 2024: 4 · 2023: 15 · 2022: 1 · 2021: 6 · 2020: 7 · 2019: 5 · 2018: 2 · 2017: 6 · 2016: 11 · 2015: 7 · 2014: 9 · 2013: 6 · 2012: 4
- FWCI
- 1.58
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Genentech
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Keywords
- HER2, trastuzumab, HER2-positive breast cancer, early intervention, tumor incidence, tumor progression, metastasis
- MeSH terms
- Trastuzumab, Animals, Antibodies, Monoclonal, Base Sequence, Enzyme-Linked Immunosorbent Assay, Female, Humans, Immunohistochemistry, Lung Neoplasms, Mammary Tumor Virus, Mouse, Mice, Transgenic, Models, Genetic, Molecular Sequence Data, Neoplasm Metastasis, Neoplasms, Experimental, Promoter Regions, Genetic, RNA, RNA, Messenger, Time Factors, Down-Regulation, Mammary Neoplasms, Animal, In Situ Hybridization, Fluorescence, Disease Progression, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Transgenes, Reverse Transcriptase Polymerase Chain Reaction, Mice, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
